SANTÉ

Big news from ABK Biomedical Inc.! The company has secured FDA approval to advance its Investigational Drug Exemption (IDE) study into Stage 2, focusing on its groundbreaking Eye90 microspheres® technology to treat unresectable Hepatocellular Cancer. This development could potentially set a new standard in personalized, image-guided cancer care.   At SANTÉ, we are proud to play a part in ABK’s journey and ongoing success. We look forward to seeing the team push the boundaries of innovation in treatment options for patients in need. https://lnkd.in/ecPJ5vNq

As a lead investor, Santé Ventures is thrilled to support Clairity, Inc. as it moves into a new chapter with the announcement of Jeffrey R. Luber Luber as President, CEO, and Director. Jeffrey is an award-winning industry leader with expertise in oncology, genetic sequencing, and digital health. With his guidance, @Clairity is set to accelerate their market launch and global expansion in delivering personalized risk assessments for breast cancer worldwide. This appointment represents a significant step forward in making the disease prediction more inclusive and accessible for all. We’re proud to be part of @Clairity’s journey in bringing real change to patient care. https://lnkd.in/gGkKjPHK

Attending the #BostonCEO event by @Longwood Healthcare Leaders this year? If so, come hear Omar H. Khalil who will be closing out day 1 with a panel discussion on October 28th.   Omar’s session, “Structuring the Syndicate,” will be at 4:40pm and will feature perspectives from top life sciences investors on how to assemble the most effective syndicates for today’s market.   Find more information on registration here: https://lnkd.in/eehfZ2xB   #VentureCapital #Biotech

Congratulations to @Endogenex who just completed their first patient enrollment in the ReCET Clinical Study. This is a major milestone, which will help address the root causes of type 2 diabetes.   Previous treatments have failed to adequately manage blood glucose levels - leaving millions of patients at higher risk of complications. Endogenex’s ReCET™ system works to reset the body’s natural metabolic processes, offering a more targeted treatment instead of symptom management.   @Santé is proud to support companies like Endogenex who are creating innovative approaches to improving healthcare and changing the way we think about this disease.   https://lnkd.in/eNGKApNt

Congratulations to Sergio Santillana on your new position as Chief Medical Officer! We are very excited to be a part of the Solu Therapeutics journey, and look forward to our continued work together.

Congratulations to @DanRose on becoming the new CEO of @EndovascularEngineering! We’re inspired by all that EE has accomplished these past few years, and we look forward to our continued work together developing and deploying the innovative Hēlo Thrombectomy System. More details on Dan and the novel Hēlo technology in this week’s release. https://lnkd.in/e8pEFmdb

Historically, the venture capital industry has overlooked weight-loss solutions – but the advent of GLP-1 medications has changed the landscape rapidly over the past few years.   Dennis McWilliams shares his perspective on the shift towards these treatments in a new Bloomberg article, highlighting recent developmental efforts to produce options with more tolerable side effects. Additionally, as patients often regain weight after stopping these drugs, companies are looking to create new strategies in managing this transition without rebounding.   While it seems that every major pharma company now has their own obesity strategy, Dennis provides thoughts on where to invest in what has become a crowded market.   https://lnkd.in/eHSqdsAG

We’re proud to play a role in the growth of @Endogenex – who this week announced an $88M Series C round! Endogenex is pioneering new approaches to treating patients with Type 2 diabetes, by resetting the body’s metabolic signaling system. The company developed an innovative ReCET System that applies precise, controlled, and non-thermal pulsed electric fields to help patients regain control of their blood glucose levels and slow disease progression. It’s a novel solution with significant promise for patients struggling with this disease. Congrats to the full team on your continued success. https://lnkd.in/eCrU2nyb

Congratulations to the full team at @GlyscendTherapuetics on today’s announcement!   The initiation of phase 2 clinical trials on GLY-200, a novel oral treatment for obesity, mark a big step forward in obesity treatment. Glyscend’s innovative approach mimics the effects of bariatric surgery with an oral drug, requiring far less of a burden on patients.   Millions of people living with obesity and type 2 diabetes, who have so far had to rely on surgery or injection treatments, will (hopefully) be able to benefit from this approach in the future. It’s one of the reasons we are proud to work with companies like Glyscend who are truly moving the needle and changing the way we think about healthcare.

The 23rd annual Medtech MVP Conference is taking place June 17-18 this year in Minneapolis, and James Eadie, Managing Director will be joining the discussion.   James will be on a panel covering the Clinical and Regulatory Strategies for Commercial Success, along with Margot G., Chief Medical Officer, SpyGlass Pharma, Sam Roosz, CEO, Crescendo Health, and Stacey Pugh CEO, Endogenex.   Even the most innovative treatments cannot impact the healthcare system if they don’t have a viable path to commercial success. This will be a great conversation on strategies to keep in mind throughout a company’s growth, and what to do when things don’t go according to plan.   If you’ll be at this year’s event, come hear the panel at 2:10 on June 18th.   https://lnkd.in/e7Uuvt6h